BCIQ Profiles

Company Profile ReportTarget Profile Report
0825 Cardior
BioCentury & Getty Images

Finance

Cardior’s €64M B round to push first-in-class heart failure program into Phase II

German company’s goal is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences.  

The goal of German biotech Cardior’s lead program is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences. 

Read the full 600 word article

How to gain access

Continue reading with a
two-week free trial.